[go: up one dir, main page]

CO2019002171A2 - Compuestos 8-(azetidín-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de utilización de los mismos. - Google Patents

Compuestos 8-(azetidín-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de utilización de los mismos.

Info

Publication number
CO2019002171A2
CO2019002171A2 CONC2019/0002171A CO2019002171A CO2019002171A2 CO 2019002171 A2 CO2019002171 A2 CO 2019002171A2 CO 2019002171 A CO2019002171 A CO 2019002171A CO 2019002171 A2 CO2019002171 A2 CO 2019002171A2
Authority
CO
Colombia
Prior art keywords
compounds
methods
azetidin
triazolo
pyridinyl
Prior art date
Application number
CONC2019/0002171A
Other languages
English (en)
Inventor
Limin Cheng
Yun-Xing Cheng
Simon Charles Goodacre
Rongbao Hua
F Anthony Romero
Mark Edward Zak
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO2019002171A2 publication Critical patent/CO2019002171A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente memoria se describen compuestos de fórmulas (I) y (II), o un estereoisómero, tautómero, solvato, profármaco o sal del mismo, y métodos de utilización como inhibidores de quinasas de Janus.
CONC2019/0002171A 2016-09-06 2019-03-08 Compuestos 8-(azetidín-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de utilización de los mismos. CO2019002171A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016098215 2016-09-06
PCT/EP2017/072034 WO2018046409A1 (en) 2016-09-06 2017-09-02 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2019002171A2 true CO2019002171A2 (es) 2019-05-21

Family

ID=59761965

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0002171A CO2019002171A2 (es) 2016-09-06 2019-03-08 Compuestos 8-(azetidín-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de utilización de los mismos.

Country Status (19)

Country Link
US (3) US20190202822A1 (es)
EP (2) EP3510030B1 (es)
JP (1) JP7050761B2 (es)
KR (1) KR20190045302A (es)
CN (1) CN109890817B (es)
AU (1) AU2017324281A1 (es)
BR (1) BR112019004486A2 (es)
CA (1) CA3035712A1 (es)
CL (1) CL2019000568A1 (es)
CO (1) CO2019002171A2 (es)
CR (1) CR20190118A (es)
IL (1) IL265153A (es)
MA (1) MA46176A (es)
MX (1) MX2019002627A (es)
PE (1) PE20190632A1 (es)
PH (1) PH12019500478A1 (es)
RU (1) RU2019109570A (es)
SG (1) SG11201901954XA (es)
WO (1) WO2018046409A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020257143A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2024148184A1 (en) * 2023-01-04 2024-07-11 Aerie Pharmaceuticals, Inc. Compounds and processes for the preparation of jak inhibitors
WO2024148186A1 (en) * 2023-01-04 2024-07-11 Aerie Pharmaceuticals, Inc. Polymorphs of a jak1/tyk2 inhibitor and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
WO1997002289A1 (en) 1995-07-06 1997-01-23 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
EP1458682B1 (en) 2001-12-20 2006-08-30 Bayer HealthCare AG 1,4-dihydro-1,4-diphenylpyridine derivatives
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
BRPI0910021A2 (pt) * 2008-06-20 2015-09-01 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinas em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
WO2010010184A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010141796A2 (en) * 2009-06-05 2010-12-09 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
PL3786162T3 (pl) * 2013-05-17 2024-04-08 Incyte Holdings Corporation Pochodne bipirazolu jako inhibitory jak
SG11201601707PA (en) * 2013-09-05 2016-04-28 Hoffmann La Roche Triazolopyridine compounds, compositions and methods of use thereof
CN107428750A (zh) * 2015-03-04 2017-12-01 豪夫迈·罗氏有限公司 三唑并吡啶化合物及其使用方法

Also Published As

Publication number Publication date
US20190202822A1 (en) 2019-07-04
US20230242530A1 (en) 2023-08-03
RU2019109570A3 (es) 2020-10-08
PH12019500478A1 (en) 2019-12-02
JP2019526593A (ja) 2019-09-19
WO2018046409A1 (en) 2018-03-15
AU2017324281A1 (en) 2019-03-21
EP4198036A1 (en) 2023-06-21
JP7050761B2 (ja) 2022-04-08
CR20190118A (es) 2019-04-30
BR112019004486A2 (pt) 2019-05-28
US20200270248A1 (en) 2020-08-27
CL2019000568A1 (es) 2019-07-12
RU2019109570A (ru) 2020-10-08
MA46176A (fr) 2019-07-17
SG11201901954XA (en) 2019-04-29
MX2019002627A (es) 2019-10-30
CN109890817A (zh) 2019-06-14
EP3510030B1 (en) 2023-03-22
CN109890817B (zh) 2022-06-17
PE20190632A1 (es) 2019-04-26
EP3510030A1 (en) 2019-07-17
KR20190045302A (ko) 2019-05-02
CA3035712A1 (en) 2018-03-15
IL265153A (en) 2019-05-30

Similar Documents

Publication Publication Date Title
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
PH12020551332A1 (en) Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
CL2019000941A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
PE20171307A1 (es) Compuestos de triazolopirimidina y usos de los mismos
PE20161388A1 (es) Inhibidores de la jak1 para el tratamiento de sindromes mielodisplasicos
MX384948B (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos.
CL2018003060A1 (es) Compuestos de pirimidina como inhibidores de la quinasa jak.
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
MX372997B (es) Compuestos de aminopirimidina como inhibidores de jak.
MX2016010571A (es) Pirazolil-ureas como inhibidores de quinasas.
EA032953B1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
PH12017501032A1 (en) 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS
BR112018005851A2 (pt) derivados de pirrolo[2,3-d]pirimidina como inibidores de dyrk1 / clk1 duais
MY197626A (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
CO2019006220A2 (es) Compuestos de pirazolopirimidina y métodos de uso de los mismos
EA201790779A1 (ru) Замещенные аминопуриновые соединения, их композиции и способы лечения с использованием таких соединений
CO2019002171A2 (es) Compuestos 8-(azetidín-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de utilización de los mismos.
CL2016000496A1 (es) Compuestos derivados de 1,2,4-triazolo[1,5-a]-piridina, inhibidores de una janus cinasa, tal como jak1; composiciones farmacológicas; útiles para el tratamiento de enfermedades inflamatorias.
AU2015295120A8 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
MX2015015290A (es) Compuestos furanona como inhibidores de quinasa.
PH12017501063A1 (en) Compounds for the treatment of cancer
CR20160539A (es) Compuestos de 2-cloro-2difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos